The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates
Open accessAbstract
Fabry disease is an X-linked lysosomal storage disease caused by loss of alpha galactosidase A (α-Gal A) activity and is characterized by progressive accumulation of globotriaosylceramide and its analogs in all cells and tissues. Although enzyme replacement therapy (ERT) is considered standard of care, the long-term effects of ERT on renal and cardiac manifestations remain uncertain and thus novel therapies are desirable. We herein report preclinical studies evaluating systemic messenger RNA (mRNA) encoding human α-Gal A in wild-type (WT) mice, α-Gal A-deficient mice, and WT non-human primates (NHPs). The pharmacokinetics and distribution of h-α-Gal A mRNA encoded protein in WT mice demonstrated prolonged half-lives of α-Gal A in tissues and plasma. Single intravenous administration of h-α-Gal A mRNA to Gla-deficient mice showed dose-dependent protein activity and substrate reduction. Moreover, long duration (up to 6 weeks) of substrate reductions in tissues and plasma were observed after a single injection. Furthermore, repeat i.v. administration of h-α-Gal A mRNA showed a sustained pharmacodynamic response and efficacy in Fabry mice model. Lastly, multiple administrations to non-human primates confirmed safety and translatability. Taken together, these studies across species demonstrate preclinical proof-of-concept of systemic mRNA therapy for the treatment of Fabry disease and this approach may be useful for other lysosomal storage disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The therapeutic potential of mRNA-based protein replacement therapies has also been tested in other metabolic disorders in preclinical studies, including hereditary tyrosinaemia type I (HTI)142, acute intermittent porphyria222,223, Fabry disease224,225, Crigler–Najjar syndrome type 1 (ref.226), α1 antitrypsin deficiency227, methylmalonic acidaemia/aciduria228, arginase deficiency229, citrin defic”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [224]
Citations
Cites
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Prevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*
Spada, M., Pagliardini, S., Yasuda, M., Tükel, T., Thiagarajan, G., Sakuraba, H., Ponzone, A., & Desnick, R. J. (2006) · The American Journal of Human Genetics · doi:10.1086/504601 · Cited by 1,007
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.010 · Cited by 820 · cited 1×
“were prepared by ethanol-drop nanoprecipitation as previously described.(30) Briefly, lipids dissolved in ethanol at a molar ratio of 50:10:38.”
MethodSelf-citationLong-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy
Weidemann, F., Niemann, M., Breunig, F., Herrmann, S., Beer, M., Störk, S., Voelker, W., Ertl, G., Wanner, C., & Strotmann, J. M. (2009) · Circulation · doi:10.1161/circulationaha.108.794529 · Cited by 489
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
Germain, D. P., Charrow, J., Desnick, R. J., Guffon, N., Kempf, J., Lachmann, R., Lemay, R. M., Linthorst, G. E., Packman, S., Scott, C. R., et al. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102797 · Cited by 365
Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease
Richner, J. M., Jagger, B. W., Shan, C., Fontes, C. R., Dowd, K. A., Cao, B., Himansu, S., Caine, E. A., Nunes, B. T. D., Medeiros, D. B. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.040 · Cited by 267
Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia
An, D., Schneller, J. L., Frassetto, A., Liang, S., Zhu, X., Park, J.-S., Theisen, M., Hong, S.-J., Zhou, J., Rajendran, R., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.081 · Cited by 263
Self-citationLee, K. (2003) · Glycobiology · doi:10.1093/glycob/cwg034 · Cited by 255
Cited by
Sorted by citations
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Unlocking the promise of mRNA therapeutics
Rohner, E., Yang, R., Foo, K. S., Goedel, A., & Chien, K. R. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01491-z · Cited by 612
The Limitless Future of RNA Therapeutics
Damase, T. R., Sukhovershin, R. A., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 577
van Spronsen, F. J., Blau, N., Harding, C. O., Burlina, A., Longo, N., & Bosch, A. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00267-0 · Cited by 506
Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs
Lokugamage, M. P., Vanover, D. A., Beyersdorf, J. P., Hatit, M. Z. C., Rotolo, L., Echeverri, E. S., Peck, H. E., Ni, H., Yoon, J., Kim, Y., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00786-x · Cited by 539
Metadata
- Authors
- Zhu, X., Yin, L., Theisen, M., Zhuo, J., Siddiqui, S., Levy, B., Presnyak, V., Frassetto, A., Milton, J., Salerno, T., Benenato, K. E., Milano, J., Lynn, A., Sabnis, S., Burke, K., Besin, G., Lukacs, C. M., Guey, L. T., Finn, P. F., & Martini, P. G. V.
- Corresponding author
- Martini, Paolo G.V.
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 104
- Issue
- 4
- Pages
- 625-637
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC6451694
- OpenAlex
- W2921621642
- Cited by
- 165
- References
- 51
- Citations by year
- 2026: 12 · 2025: 30 · 2024: 26 · 2023: 20 · 2022: 32 · 2021: 23 · 2020: 14 · 2019: 8
- FWCI
- 13.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Moderna
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- Fabry disease, alpha-galactosidase A, globotriaosylceramide, lysosomal storage disease, enzyme replacement therapy, pharmacokinetics, pharmacodynamics, non-human primates, substrate reduction, X-linked disorders
- MeSH terms
- alpha-Galactosidase, Fabry Disease, Animals, Disease Models, Animal, Endocytosis, Humans, Lipids, Lysosomes, Macaca fascicularis, Male, RNA, Messenger, Tissue Distribution, Trihexosylceramides, Genetic Therapy, Mice, Knockout, Mice, Enzyme Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
